EpiCast Report: Non-Alcoholic Steatohepatitis – Epidemiology Forecast to 2025
- Pages: 55
- Published: December 2016
- Report Code: GDHCER139-16
Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of steatosis (fatty liver), in addition to liver inflammation and damage. Unlike alcoholic liver disease, NASH occurs in those who drink little or no alcohol. NASH usually presents with few or no symptoms, and most people affected with the disease feel healthy and are unaware they have a problem.
GlobalData epidemiologists forecast that the total prevalent cases of NASH in the 7MM will grow by 0.64% per year over the next 10 years, from 61,295,898 cases in 2016, to 65,201,742 cases in 2026. In the 7MM, the US will have the highest number of total prevalent cases throughout the forecast period, accounting for 57.06% of all total prevalent cases in the 7MM in 2016. When analyzing the individual markets, more than 85.00% of the total prevalent cases of NASH occurred in ages 20 years and older and more cases occurred in men compared with women. GlobalData epidemiologists forecast that the 7MM will see an increase in the diagnosed prevalent cases of NASH from 18,525,895 cases in 2016 to 31,407,526 cases in 2026, at the rate of 6.95%. Diagnosed prevalent cases are forecast to increase faster than total prevalent cases due to expected increase in diagnosis rate, as indicated by primary research.
GlobalData epidemiologists utilized primary research and comprehensive, country-specific data from peer-reviewed journal articles when available, to arrive at a meaningful, in-depth analysis and forecast for the total and diagnosed prevalent cases of NASH. Since obesity is a major risk factor for NASH, the prevalence trend in obesity was used to determine the prevalence trend in NASH across all age- and sex-specific segmentations, thereby providing granularity to the forecast analysis. The forecast is further strengthened by the use of a biopsy-proven total prevalence study to estimate the total prevalence of NASH in the 7MM, excluding Japan, as liver biopsies are regarded as the gold-standard diagnostic method for NASH. In Japan, clinically relevant noninvasive diagnostic indices were combined to estimate the total prevalence in Japan. Finally, the forecast methodology was consistent across all markets to allow for meaningful global comparisons of the total and diagnosed prevalent cases of NASH.
The Non-Alcoholic Steatohepatitis (NASH) EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends of NASH in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases (both diagnosed and undiagnosed) of NASH segmented by age and sex. It also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of NASH, which are further segmented by comorbid disorders, including obesity, diabetes mellitus type 2 (T2D), hyperlipidemia, and hypertension in these markets.
The NASH epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Reasons to buy
The NASH EpiCast series will allow you to:
Develop business strategies by understanding the trends shaping and driving the global NASH market.
Quantify patient populations in the global NASH market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for NASH therapeutics in each of the markets covered.
Identify the percentage of NASH prevalent cases by comorbidity.
Table of Contents
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2.1 Risk Factors and Comorbidities
2.2 Global Trends
2.3 Forecast Methodology
2.3.1 Sources Used Tables
2.3.2 Forecast Assumptions and Methods
2.3.3 Sources Not Used
2.4 Epidemiological Forecast for NASH (2016–2026)
2.4.1 Total Prevalent Cases of NASH
2.4.2 Age-Specific Total Prevalent Cases of NASH
2.4.3 Sex-Specific Total Prevalent Cases of NASH
2.4.4 Age-Standardized Prevalence of NASH
2.4.5 Diagnosed Prevalent Cases of NASH
2.4.6 Diagnosed Prevalent Cases of NASH by Comorbid Disorder
2.5.1 Epidemiological Forecast Insight
2.5.2 Limitations of the Analysis
2.5.3 Strengths of the Analysis
3.2 Physicians and Specialists Included in this Study
3.3 About the Authors
3.3.3 Global Director of Therapy Analysis and Epidemiology
3.4 About GlobalData
3.5 About EpiCast
3.6 Contact Us
List of Tables
Table 1: Risk Factors and Comorbidities for NASH
Table 2: 7MM, Sources of Epidemiological Data Used to Forecast Total Prevalent Cases of NASH
Table 3: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of NASH
Table 4: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of NASH by Comorbid Disorder
Table 5: 7MM, Total Prevalent Cases of NASH, Both Sexes, Ages ≥4 Years, Select Years, 2016–2026
Table 6: 7MM, Age-Specific Total Prevalent Cases of NASH, Both Sexes, N (Row %), 2016
Table 7: 7MM, Sex-Specific Total Prevalent Cases of NASH, Ages ≥4 Years, N (Row %), 2016
Table 8: 7MM, Diagnosed Prevalent Cases of NASH, Both Sexes, Ages ≥4 Years, Select Years, 2016–2026
Table 9: 7MM, Diagnosed Prevalent Cases of NASH, by Comorbid Disorder, Ages ≥4 Years, N (Row %), 2016
Table 10: High-Prescribing Physicians (non-KOLs) Surveyed, by Country
List of Figures
Figure 1: 5EU, Total Prevalence of NAFLD and Obesity (%), Ages ≥20 Years, Both Sexes
Figure 2: 7MM, Total Prevalent Cases of NASH, Both Sexes, Ages ≥4 Years, Selected Years, 2016–2026
Figure 3: 7MM, Age-Specific Total Prevalent Cases of NASH, Both Sexes, 2016
Figure 4: 7MM, Sex-Specific Total Prevalent Cases of NASH, Ages ≥4 Years, 2016
Figure 5: 7MM, Age-Standardized Total Prevalence of NASH, Ages ≥4 Years, 2016
Figure 6: 7MM, Diagnosed Prevalent Cases of NASH, Both Sexes, Ages ≥4 Years, Selected Years, 2016–2026
Figure 7: 7MM, Diagnosed Prevalent Cases of NASH, by Comorbid Disorder, Ages ≥4 Years, N, 2016